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Reflux esophagitis triggered after
Helicobacter pylori eradication: a
noteworthy demerit of eradication
therapy among the Japanese?
Katsunori Iijima*, Tomoyuki Koike and Tooru Shimosegawa
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
In the February 2013 Revision of Insured Medical Treatment, bacterial eradication for
all Helicobacter pylori-positive individuals in Japan was covered under the insurance
scheme. However, reflux esophagitis is believed to occur in approximately 10% of
Japanese patients who undergo eradication therapy. Hence, the risk of reflux esophagitis
among such cases should be carefully considered, particularly in the treatment for H.
pylori-positive patients who are otherwise healthy. The eradication of H. pylori in cases of
H. pylori-positive gastritis markedly suppresses gastric inflammation, and inhibits gastric
mucosal atrophy and its progression to intestinal metaplasia. In a long-term follow-up
study (10–20 years), eradication treatment was found to reduce the risk of subsequent
gastric cancer. However, the fact that eradication-induced reflux esophagitis could
increase the long-term risk of Barrett’s esophagus and esophageal adenocarcinoma
should also be considered in the Japanese population. Appropriate treatment with proton
pump inhibitors should be taken into consideration for patients undergoing eradication
therapy in clinical practice.
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Introduction
Eradication of Helicobacter pylori (H. pylori) in cases of H. pylori-positive gastritis markedly
suppresses gastric inflammation, and inhibits gastric mucosal atrophy and its progression to
intestinal metaplasia. Therefore, eradication therapy has been found to reduce the risk of
subsequent gastric cancer not only in high-risk group of patients such as those who have undergone
endoscopic resection for early gastric cancer (Fukase et al., 2008) but also in healthy asymptomatic
infected individuals (Fuccio et al., 2009; Ma et al., 2012; Ford et al., 2014). Thus far, two meta-
analyses consistently indicated that H. pylori eradication significantly reduce the risk of gastric
cancer with relative risk (95% CI): 0.65 (0.43–0.98) and 0.66 (0.46–0.95) (Fuccio et al., 2009; Ford
et al., 2014), and a single study successfully revealed its significant preventive effect among more
than 3000 subjects with long-term follow-up such as 10–20 years with relative risk (95% CI):
0.61 (0.38–0.96) (Ma et al., 2012). Meanwhile, the occurrence of reflux esophagitis after H. pylori
eradication was first reported in Europe in 1997 (Labenz et al., 1997). Since then, several conflicting
results regarding the causal relationship between eradication therapy and reflux esophagitis have
been reported. In this article, we describe the association between H. pylori infection and reflux
esophagitis and review the literature on post-eradication reflux esophagitis.
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Effect of H. pylori Infection on Gastric Acid
Secretion and its Association with
Gastroesophageal Reflux Disease
Several meta-analyses have confirmed that H. pylori infection
is inversely correlated with the occurrence of a large spectrum
of gastroesophageal reflux diseases (GERDs), ranging from
erosive esophagitis and Barrett’s esophagus (BE) to esophageal
adenocarcinoma (Raghunath et al., 2003; Rokkas et al., 2007;
Wang et al., 2009; Fischbach et al., 2012; Xie et al., 2013a,b).
This association is more pronounced in Asia, although it has
also been observed in Western countries (Raghunath et al., 2003;
McColl, 2004; Xie et al., 2013a,b). With regard to the mechanism
underlying the inhibition of GERD onset by gastric H. pylori
infection, the effect of H. pylori on gastric acid secretion and
the manner in which the infection modifies GERDmanifestation
through the reflux of gastric acid into the esophagus are
important.
The effect of H. pylori infection on gastric acid secretion
is associated with the spread of infection-associated gastritis
(Atherton and Blaser, 2009). In some cases, the region involved
in gastric acid secretion in the stomach body is largely unaffected
by H. pylori infection and the associated gastric inflammation
in the gastric antrum; therefore, the secretion of gastric acid is
not reduced. In addition, the infection also results in elevated
serum gastrin levels. In such cases, the risk ofH. pylori infection-
associated GERD does not decrease, but is, in fact, believed to
increase (Iijima et al., 2000). On the other hand, in cases where
gastric inflammation caused by H. pylori infection affects the
entire stomach body (region involved in gastric acid secretion),
the suppressive effect induced by inflammatory cells on parietal
cells reduces gastric acid secretion. Furthermore, prolonged
inflammation of the stomach body results in a decrease in the
number of parietal cells owing to gastric mucosal atrophy, thus
further reducing acid secretion (Iijima et al., 2004a). Therefore, in
cases where H. pylori infection suppresses gastric acid secretion,
the level of gastric acid produced during gastric reflux decreases;
this process is considered to be the main mechanism through
whichH. pylori infection inhibits the onset of GERD (Koike et al.,
2001a; Abe et al., 2004; Inomata et al., 2006).
The extent to which H. pylori infection reduces acid secretion
greatly differs according to the patient’s race. Although gastric
acid secretion levels were found to remain constant in most
patients with H. pylori infection from Western countries
(Katelaris et al., 1993; Peterson et al., 1993), the majority
of Japanese patients with H. pylori infection (mostly elderly
individuals) exhibited decreased acid secretion (Iijima et al.,
2004b, 2014). Thus, host racial differences in the effect of H.
pylori infection on gastric acid secretion could be responsible for
the different degree of inhibitory effect of the infection on the
manifestation of GERD between Asian and Western countries.
Reflux Esophagitis after H. pylori
Eradication
Moreover, no consensus has been reached on whether H. pylori
eradication leads to the onset of reflux esophagitis. There
have been some meta-analyses regarding effects of H. pylori
eradication on the occurrence of GERD (Raghunath et al.,
2004; Yaghoobi et al., 2010; Saad et al., 2012; Xie et al.,
2013a). Of these, two meta-analyses failed to find any significant
association between the two factors (Raghunath et al., 2004;
Saad et al., 2012), and one meta-analysis showed that although
there was no significant association in overall analysis, H.
pylori eradication was significantly associated with the risk of
subsequently developing GERD among peptic ulcer patients with
relative risk (95% CI): 2.0 (1.1–3.9) (Yaghoobi et al., 2010).
Another meta-analysis comprising 12 randomized controlled
studies showed that H. pylori eradication led to a higher risk of
GERDwith relative risk (95% CI): 2.0 (1.2–3.2) (Xie et al., 2013a).
The possible reasons underlying the lack of a consensus include
geographic differences and differences between the diseases
for which eradication was performed. First, the geographic
differences could explain the conflicting results as one meta-
analysis clearly indicated that the risk was significant in the
subgroup analysis of Asian studies while it was not observed in
that of Western studies with relative risk (95% CI): 4.5 (1.7–
12.4) vs. 1.2 (0.9–1.6) (Xie et al., 2013a). Yet, other meta-analyses
included only a few Asian studies, and they did not perform
subgroup analysis in different regional areas (Raghunath et al.,
2004; Yaghoobi et al., 2010; Saad et al., 2012). As mentioned
previously, this regional difference is attributed to the racial
differences in the effect of H. pylori infection on gastric acid
secretion. In Europeans and Americans, H. pylori infection does
not lead to amajor change in gastric acid secretion, and aminimal
increase is observed after eradication (Katelaris et al., 1993;
Peterson et al., 1993). In contrast, in Asians, H. pylori infection
is associated with decreased gastric acid secretion in the majority
of the cases (Iijima et al., 2004b, 2014); therefore, eradication is
believed to result in the recovery of gastric acid secretion (Koike
et al., 2001b).
Furthermore, the wide variance in reports concerning the
likelihood of reflux esophagitis after eradicationmay be explained
by the difference in the diseases for which eradication is
performed. For example, in cases with H. pylori-positive gastric
ulcers, reflux esophagitis is known to occur frequently after
eradication (Koike et al., 2001b). On the other hand, in cases
with duodenal ulcers, the risk of reflux esophagitis is low; in
fact, eradication has been reported to improve the previously
existing reflux esophagitis in such cases (Ishiki et al., 2004).
Therefore, disease-related differences in the acid secretion
changes associated with eradication are believed to play a role in
the occurrence reflux esophagitis after eradication (Koike et al.,
2001a).
On the other hand, increased gastric acid secretion may
be a necessary but not a sufficient factor for developing
reflux esophagitis after eradication, since a previous study
using simultaneous 24 h pH determination in the stomach
and esophagus demonstrated that increased gastric acidity after
eradication was not accompanied by concomitant increase in
gastroesophageal acid reflux (Fukuchi et al., 2005). In addition
to increased gastric acid secretion, impairment of anti-reflux
mechanism from the stomach into the esophagus such as hiatal
hernia may also be important for developing reflux esophagitis
after eradication (Hamada et al., 2000; Koike et al., 2001b; Inoue
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et al., 2004; Kawanishi, 2005). In fact, Koike et al. reported that
reflux esophagitis occurred after eradication only in patients with
hiatal hernia (Koike et al., 2001b).
A previous study, which examined hospitalized patients with a
variety of diseases who underwent eradication in Japan, reported
that the frequency of post-eradication reflux esophagitis was 10–
18% (Hamada et al., 2000; Koike et al., 2001b; Inoue et al.,
2004; Kawanishi, 2005; Take et al., 2009). The post-eradication
follow-up examination revealed many cases of patients in whom
reflux esophagitis manifested transiently after the eradication and
disappeared after several years (Take et al., 2009). In addition,
proton pump inhibitors (PPIs) treatment should be effective for
curing reflux esophagitis after eradication, although the drugs
do not need to be administered to all patients undergoing
eradication therapy given that only a sub-group of patients suffer
from the disease after eradication. In the future, the course of
post-eradication reflux esophagitis (i.e., the percentage of cases
in which reflux esophagitis progresses to BE and esophageal
adenocarcinoma) should be observed closely with a long-term
follow-up (10–20 years).
Post-Eradication Reflux Esophagitis in
Healthy Asymptomatic H. pylori-Infected
Japanese Individuals
Since February 2013, the Japanese national health insurance has
covered eradication therapy for all H. pylori-positive patients
with chronic gastritis, with an aim of reducing the risk of the
subsequent development of gastric cancer (Asaka, 2013); hence,
eradication therapy is more widely administered at present.
Therefore, the estimation of the risk of reflux esophagitis after
eradication therapy in H. pylori-positive, asymptomatic, healthy
individuals is important. A recent large-scale cross-sectional
study in healthy Japanese subjects indicated that there was a
significant difference in the prevalence of reflux esophagitis
between the subjects with chronic H. pylori infection and those
who underwent successful eradication (2.3 vs. 8.8%) (Minatsuki
et al., 2013). However, thus far, the risk of post-eradication reflux
esophagitis in the H. pylori-positive population has not been
assessed in a prospective cohort study in Japan. One report
on the efficacy of eradication therapy in 841 H. pylori-positive
patients in Taiwan, which is in close proximity to Japan, stated
that eradication increased the morbidity associated with reflux
esophagitis from 13.7 to 27.3% (Lee et al., 2013). In a Korean
study involving 421 patients who underwent health check-
ups, reflux esophagitis developed in 10.0% of the patients who
underwent eradication compared to 4.3% of the patients who
did not undergo eradication; thus, the eradication group showed
a significantly higher morbidity (Nam et al., 2010). These data
indicate that when eradication therapy is administered to the
H. pylori-positive population in Asia, the morbidity associated
with reflux esophagitis is likely to increase in a sub-group of the
subjects.
A potential merit of eradication for patients with peptic
ulcers, mucosa-associated lymphoid tissue (MALT) lymphoma,
or those who undergo endoscopic resection for early gastric
cancer, should obviously outweigh the demerits of the therapy
including the de novo development of reflux esophagitis. Hence,
eradication therapy should not be avoided for these patients
due to the risk of developing GERD. Even if GERD develops
after eradication, PPI treatment should be effective for curing
such disorder. However, eradication-induced reflux esophagitis
could in theory increase the long-term risk of BE and esophageal
adenocarcinoma (Abe et al., 2011). Hence, the preventive effect
of H. pylori eradication on gastric cancer should be carefully
considered at the cost of increasing the risk of reflux esophagitis,
in the treatment of healthy asymptomatic individuals with H.
pylori infection (Blaser, 2010), particularly in Asian populations.
Presence of hiatal hernia (Hamada et al., 2000; Koike et al., 2001b;
Inoue et al., 2004; Kawanishi, 2005), body gastritis (Hamada et al.,
2000; Koike et al., 2001b), and older age (Koike et al., 2001b; Take
et al., 2009) are identified as risk factors for reflux esophagitis after
H. pylori eradication in Japan, hence careful attention needs to be
taken in treating such patients.
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